{"title":"Overall Incidence of Postoperative Pancreatic Fistula After Early Drain Removal in Distal Pancreatectomy.","authors":"Teruhisa Sakamoto, Jun Yoshida, Mikiya Kishino, Yuki Murakami, Kozo Miyatani, Yuji Shishido, Kyoichi Kihara, Manabu Yamamoto, Tomoyuki Matsunaga, Naruo Tokuyasu, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17553","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Detailed evaluation of the overall incidence of postoperative pancreatic fistula (POPF) after early drain removal (EDR) in distal pancreatectomy (DP) is lacking. This study aimed to assess postoperative complications, including the overall incidence of POPF, with EDR following DP.</p><p><strong>Patients and methods: </strong>Ninety-nine patients who underwent EDR after DP regardless of drain fluid amylase level between January 2017 and December 2024 were enrolled in this study. Data were retrospectively analyzed to evaluate complications, including the overall incidence of POPF.</p><p><strong>Results: </strong>The overall incidence of POPF after EDR was 31.3% (31/99 patients), of which the incidence of clinically relevant POPF requiring reinsertion of abdominal drains was 4.0% (4/99 patients). The incidence of Clavien-Dindo grade ≤ II POPF was high, at 27.3% (27/99 patients). There were no complications of Clavien-Dindo grade IV or V. Univariate analysis of pre- and intraoperative variables showed that injury to the pancreatic parenchyma near the pancreatic stump was the only risk factor for drain reinsertion after EDR.</p><p><strong>Conclusion: </strong>EDR, regardless of drain fluid amylase level, reduces the incidence of Clavien-Dindo grade ≥ IIIa POPF after DP. However, EDR does not necessarily contribute to a decrease in the overall incidence of POPF after DP.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1723-1730"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17553","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Detailed evaluation of the overall incidence of postoperative pancreatic fistula (POPF) after early drain removal (EDR) in distal pancreatectomy (DP) is lacking. This study aimed to assess postoperative complications, including the overall incidence of POPF, with EDR following DP.
Patients and methods: Ninety-nine patients who underwent EDR after DP regardless of drain fluid amylase level between January 2017 and December 2024 were enrolled in this study. Data were retrospectively analyzed to evaluate complications, including the overall incidence of POPF.
Results: The overall incidence of POPF after EDR was 31.3% (31/99 patients), of which the incidence of clinically relevant POPF requiring reinsertion of abdominal drains was 4.0% (4/99 patients). The incidence of Clavien-Dindo grade ≤ II POPF was high, at 27.3% (27/99 patients). There were no complications of Clavien-Dindo grade IV or V. Univariate analysis of pre- and intraoperative variables showed that injury to the pancreatic parenchyma near the pancreatic stump was the only risk factor for drain reinsertion after EDR.
Conclusion: EDR, regardless of drain fluid amylase level, reduces the incidence of Clavien-Dindo grade ≥ IIIa POPF after DP. However, EDR does not necessarily contribute to a decrease in the overall incidence of POPF after DP.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.